



## Fezolinetant for Moderate to Severe Vasomotor Symptoms Associated with Menopause: Effectiveness and Value

Friday • December 16, 2022 • 10:00 AM – 4:00 PM CT

Virtual Event – Zoom Webinar

Registration: [https://us02web.zoom.us/webinar/register/WN\\_tdJuAbaVSfesLtMQB5pn6w](https://us02web.zoom.us/webinar/register/WN_tdJuAbaVSfesLtMQB5pn6w)

Time (CT)	Activity
10:00 am – 10:20 am	<b>Meeting Convened and Opening Remarks</b> Steven D. Pearson, MD, MSc President, ICER
10:20 am – 11:00 am	<b>Presentation of the Clinical Evidence</b> Francesca L. Beaudoin, MD, PhD, MS Senior Medical Advisor, ICER
11:00 am – 11:40 am	<b>Presentation of the Economic Model</b> R. Brett McQueen, PhD Assistant Professor, School of Pharmacy, University of Colorado
11:40 pm – 12:00 pm	<b>Public Comments and Discussion</b>
12:00 pm – 12:50 pm	<b>Lunch Break</b>
12:50 pm – 1:50 pm	<b>Midwest CEPAC Vote on Clinical Effectiveness and Value</b>
1:50 pm – 2:00 pm	<b>Break</b>
2:00 pm – 3:30 pm	<b>Policy Roundtable</b>
3:30 pm – 4:00 pm	<b>Reflections from Midwest CEPAC</b>
4:00 pm	<b>Meeting Adjourned</b>

### ICER Staff and Consultants

<b>Francesca Beaudoin, MD, PhD, MS</b> , Senior Medical Advisor, ICER	<b>Brett McQueen, PhD</b> , Assistant Professor, Department of Clinical Pharmacy, University of Colorado
<b>Grace Lin, MD</b> , Medical Director for Health Technology Assessment, ICER	<b>Eric Gutierrez, MPH</b> , Professional Research Assistant, University of Colorado
<b>Abigail Wright, PhD, MSc</b> , Senior Research Lead, Evidence Synthesis, ICER	<b>Kelsey Gosselin, MA</b> , Program Manager, ICER
<b>Serina Herron-Smith, BA</b> , Associate Research Manager, ICER	<b>Yasmine Kayali, BA</b> , Program Coordinator, ICER
<b>Ashton Moradi, PharmD, MS</b> , Health Economist, ICER	<b>David Rind, MD</b> , Chief Medical Officer, ICER
<b>Shahariar Mohammed Fahim, PhD</b> , Research Lead, Evidence Synthesis, ICER	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

### Participating Members of Midwest CEPAC

<b>Alan Balch, PhD</b> CEO, National Patient Advocate Foundation	<b>Bradley Martin, PharmD, PhD</b> Professor, University of Arkansas for Medical Sciences
<b>Bijan Borah, PhD</b> Professor of Health Services Research, Mayo Clinic College of Medicine and Science	<b>Timothy McBride, PhD</b> Professor, Washington University in St. Louis, and Co-Director, Center for Health Economics and Policy
<b>Donald Casey, MD, MPH, MBA, MACP</b> Associate Professor of Internal Medicine, Rush Medical College	<b>Reem Mustafa, MD, MPH, PhD</b> Associate Professor of Medicine, University of Kansas Medical Center, and Director, Outcomes and Implementation Research, University of Kansas Medical Center
<b>Gregory Curfman, MD</b> Interim Executive Editor, JAMA	<b>Kay Scanlan, JD</b> Senior Policy Adviser, Haystack Project
<b>Yngve Falck-Ytter, MD, AGAF</b> Professor of Medicine, Case Western Reserve University, and Chief, Gastroenterology and Hepatology VA Northeast Ohio Healthcare System, Cleveland	<b>Kurt Vanden Bosch, PharmD</b> System Formulary Lead, St. Luke's Health System
<b>Elbert Huang, MD, MPH</b> Professor of Medicine and Public Health Sciences, University of Chicago	<b>Timothy Wilt, MD, MPH</b> Professor, Medicine and Public Health University of Minnesota, and Staff Physician at the Minneapolis VA Center for Care Delivery and Outcomes Research
<b>Jill Johnson, PharmD</b> Professor, UAMS College of Pharmacy	<b>Stuart Winston, DO</b> Patient Experience Consultant, Trinity Health IHA

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<b>Shontelle Dodson, PharmD</b> , Executive Vice President, Head Medical Affairs, Astellas Pharma Inc.	Dr. Dodson is a full-time employee of Astellas Pharma Inc.
<b>Stephanie Faubion, MD, MBA</b> , Director, Center for Women's Health, Mayo Clinic. Medical Director, North American Medical Society	No conflicts to disclose
<b>Claire Gill</b> , Founder, National Menopause Foundation (NMF)	The NMF received program-specific support totaling less than 25% from Astellas Pharma, Inc.
<b>Deb Grady, MD, MPH</b> , Professor of Medicine, UCSF	No conflicts to disclose

<p><b>Paula Green-Smith, MA</b>, Chief Training Officer, Black Women’s Health Imperative (BWHI)</p>	<p>Black Women’s Health Imperative receives funding from Hologic Inc., Gilead Sciences, and Myovant-Pfizer.</p>
<p><b>Michelle Rogers, PharmD, BCPS</b>, Director, Clinical Pharmacy, IPD Analytics</p>	<p>Dr. Rogers is a full-time employee of IPD Analytics</p>
<p><b>John Watkins, PharmD, MPH, BCPS</b>, Residency Program Director, Premera Blue Cross, and Affiliate Professor, University of Washington</p>	<p>Dr. Watkins is a half-time employee of Premera Blue Cross.</p>